124 related articles for article (PubMed ID: 24931722)
1. Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients.
Gattolliat CH; Le Teuff G; Combaret V; Mussard E; Valteau-Couanet D; Busson P; Bénard J; Douc-Rasy S
Cancer Med; 2014 Aug; 3(4):998-1009. PubMed ID: 24931722
[TBL] [Abstract][Full Text] [Related]
2. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma.
Gattolliat CH; Thomas L; Ciafrè SA; Meurice G; Le Teuff G; Job B; Richon C; Combaret V; Dessen P; Valteau-Couanet D; May E; Busson P; Douc-Rasy S; Bénard J
Br J Cancer; 2011 Oct; 105(9):1352-61. PubMed ID: 21970883
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.
Liu N; Chen NY; Cui RX; Li WF; Li Y; Wei RR; Zhang MY; Sun Y; Huang BJ; Chen M; He QM; Jiang N; Chen L; Cho WC; Yun JP; Zeng J; Liu LZ; Li L; Guo Y; Wang HY; Ma J
Lancet Oncol; 2012 Jun; 13(6):633-41. PubMed ID: 22560814
[TBL] [Abstract][Full Text] [Related]
5. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
[TBL] [Abstract][Full Text] [Related]
7. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
[TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
[TBL] [Abstract][Full Text] [Related]
10. A 3-miRNA signature predicts survival of patients with hypopharyngeal squamous cell carcinoma after post-operative radiotherapy.
Xu X; Lu Z; Gross N; Li G; Zhang F; Lei D; Pan X
J Cell Mol Med; 2019 Dec; 23(12):8280-8291. PubMed ID: 31578816
[TBL] [Abstract][Full Text] [Related]
11. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma.
Romani C; Salviato E; Paderno A; Zanotti L; Ravaggi A; Deganello A; Berretti G; Gualtieri T; Marchini S; D'Incalci M; Mattavelli D; Piazza C; Bossi P; Romualdi C; Nicolai P; Bignotti E
Theranostics; 2021; 11(6):2987-2999. PubMed ID: 33456584
[TBL] [Abstract][Full Text] [Related]
13. A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer.
Wu YS; Lin H; Chen D; Yi Z; Zeng B; Jiang Y; Ren G
Gene; 2019 May; 697():86-93. PubMed ID: 30779946
[TBL] [Abstract][Full Text] [Related]
14. A novel multidimensional signature predicts prognosis in hepatocellular carcinoma patients.
Wang S; Zhang JH; Wang H; Yang L; Hong S; Yu B; Guo JC; Liu J; Zhu YB
J Cell Physiol; 2019 Jul; 234(7):11610-11619. PubMed ID: 30480822
[TBL] [Abstract][Full Text] [Related]
15. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
16. A P53-related microRNA model for predicting the prognosis of hepatocellular carcinoma patients.
Fang SS; Guo JC; Zhang JH; Liu JN; Hong S; Yu B; Gao Y; Hu SP; Liu HZ; Sun L; Zhao Y
J Cell Physiol; 2020 Apr; 235(4):3569-3578. PubMed ID: 31556110
[TBL] [Abstract][Full Text] [Related]
17. Identifying High-Risk Stage II Colon Cancer Patients: A Three-MicroRNA-Based Score as a Prognostic Biomarker.
Caritg O; Navarro A; Moreno I; Martínez-Rodenas F; Cordeiro A; Muñoz C; Ruiz-Martinez M; Santasusagna S; Castellano JJ; Monzó M
Clin Colorectal Cancer; 2016 Dec; 15(4):e175-e182. PubMed ID: 27247088
[TBL] [Abstract][Full Text] [Related]
18. MiRNAs as molecular biomarkers in stage II egyptian colorectal cancer patients.
Bahnassy AA; Salem SE; El-Sayed M; Khorshid O; Abdellateif MS; Youssef AS; Mohanad M; Hussein M; Zekri AN; Ali NM
Exp Mol Pathol; 2018 Dec; 105(3):260-271. PubMed ID: 30213464
[TBL] [Abstract][Full Text] [Related]
19. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
20. Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma.
Nordmo C; Glehr G; Altenbuchinger M; Spang R; Ziepert M; Horn H; Staiger AM; Ott G; Schmitz N; Held G; Einsele H; Topp M; Rosenwald A; Rauert-Wunderlich H
Leuk Lymphoma; 2021 May; 62(5):1107-1115. PubMed ID: 33353431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
